Company intelligence / Profile preview

TearScience

Morrisville, North Carolina, United Statesjnjvisionpro.com ↗

Ownership: Private
Employees: ~75
Development stage: Commercial

Overview

TearScience developed the first integrated in-office system to diagnose and treat evaporative dry eye caused by meibomian gland dysfunction. Its flagship products—LipiFlow and LipiView—are FDA-cleared, CE-marked, commercially available globally, and have demonstrated significant clinical improvement in patients with chronic dry eye.[1][5][6] The company was recognized for pioneering a new standard of care for MGD.

Therapeutic areas: Ophthalmology
Modalities: DeviceNon-pharmacological therapy (thermal pulsation)
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on TearScience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TearScience.

Explore the full profile